Reshape Lifesciences Q2 EPS $(0.06) Up From $(1.08) YoY, Sales $1.97M Miss $2.21M Estimate
Reshape Lifesciences Q2 EPS $(0.06) Up From $(1.08) YoY, Sales $1.97M Miss $2.21M Estimate
reshape lifesciences Q2每股收益爲$(0.06)，同比$(1.08)增長，銷售額197萬美元，未達到221萬美元的預估。
Reshape Lifesciences (NASDAQ:RSLS) reported quarterly losses of $(0.06) per share. This is a 94.44 percent increase over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $1.97 million which missed the analyst consensus estimate of $2.21 million by 11.09 percent. This is a 12.82 percent decrease over sales of $2.25 million the same period last year.
Reshape Lifesciences（納斯達克：RSLS）報告每股虧損$（0.06）。相比去年同期的每股虧損$（1.08），增長了94.44％。公司本季度銷售額爲197萬美元，低於分析師預期的221萬美元，下降了11.09％。這是與去年同期的銷售額225萬美元相比下降了12.82％。